Tirzepatide vs Ozempic (Semaglutide) UAE: Which Is Better for Weight Loss?

The first direct head-to-head trial between these two medications has given us a clear answer — and it matters for every UAE expat weighing up their GLP-1 options in Dubai.

For years, anyone trying to choose between tirzepatide and semaglutide in the UAE had to rely on indirect comparisons from separate trials with different patient populations. That changed in 2025. The SURMOUNT-5 trial — the first randomised head-to-head study comparing both drugs at their highest approved weight-loss doses — found that tirzepatide produced approximately 47% more weight loss than semaglutide over 72 weeks (New England Journal of Medicine, 2025). Both medications are MOHAP-approved and available in the UAE. The question is which one suits your situation.

This article breaks down the mechanism behind each drug, the SURMOUNT-5 trial results, side effect differences, and UAE pricing — so you can have an informed conversation with your Dubai doctor. For full sourcing and dosing detail on tirzepatide, see our tirzepatide UAE complete guide.

TL;DR

Tirzepatide (Mounjaro/Zepbound) outperformed semaglutide (Ozempic/Wegovy) in the SURMOUNT-5 head-to-head trial: 20.2% vs 13.7% mean body weight reduction — roughly 47% more weight loss (NEJM, 2025). Side effect profiles are comparable. Tirzepatide costs more in the UAE but delivers meaningfully stronger outcomes for most patients. Semaglutide has stronger cardiovascular outcome data. A UAE doctor should make the final call.

[IMAGE: Side-by-side medication comparison graphic showing two injection pens — search terms: "injection pen weight loss medication comparison"]

How Do Tirzepatide and Semaglutide Work Differently?

Tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Semaglutide activates only the GLP-1 receptor. That additional GIP pathway amplifies fat burning, improves insulin sensitivity, and produces stronger appetite suppression than GLP-1 stimulation alone (Nature Medicine, 2022). It's a genuine biological difference — not a marketing distinction.

What GLP-1 receptor activation does

GLP-1 receptor agonists slow gastric emptying, reduce hunger signals in the brain, and trigger insulin release after meals. Both drugs work this way. You feel full faster, eat less overall, and blood sugar stays more stable following food intake. This is the shared foundation of their effectiveness.

What the GIP receptor adds

GIP (glucose-dependent insulinotropic polypeptide) plays a distinct role in fat metabolism and energy storage. When tirzepatide activates this receptor alongside GLP-1, it appears to accelerate the body's ability to burn stored fat — particularly visceral fat around the abdomen. Researchers believe this dual action is why tirzepatide consistently outperforms single-agonist GLP-1 drugs across trials.

What Does the SURMOUNT-5 Trial Actually Show?

SURMOUNT-5 is the study that settled the debate. Published in the New England Journal of Medicine in early 2025, it enrolled 751 adults with obesity (no type 2 diabetes) and randomised them to tirzepatide 10mg/15mg or semaglutide 2.4mg — both at maximum approved weight-loss doses. After 72 weeks, tirzepatide produced a mean weight reduction of 20.2% versus 13.7% for semaglutide, a difference of approximately 47% (NEJM, 2025). For context on where newer triple-agonist options fit, see our retatrutide vs tirzepatide vs semaglutide comparison.

In absolute terms, that gap translates to roughly 6 kg more weight lost on tirzepatide at comparable starting weights. At a mean baseline of approximately 108 kg, the tirzepatide group lost about 22 kg versus 15 kg on semaglutide. That's a meaningful clinical difference.

Who responded best to tirzepatide?

The benefit was consistent across subgroups — men, women, varying BMI ranges, and different ethnic backgrounds. Participants with higher starting BMI tended to lose more in absolute kilograms, but the percentage gap between the two drugs remained roughly constant. There was no identified subgroup where semaglutide clearly outperformed tirzepatide.

How do the older individual trial numbers compare?

Before SURMOUNT-5, researchers compared across separate trials with different patient populations — an imperfect method. The SURMOUNT-1 tirzepatide trial showed up to 22.5% weight loss at 15mg (NEJM, 2022). The STEP-1 semaglutide trial showed 14.9% at 2.4mg (NEJM, 2021). The indirect comparison always suggested tirzepatide was ahead. SURMOUNT-5 confirmed it under identical controlled conditions.

[CHART: Bar chart — Mean % body weight loss at 72 weeks: Tirzepatide 20.2% vs Semaglutide 13.7% — Source: NEJM SURMOUNT-5, 2025]

Tirzepatide vs Semaglutide: Full Head-to-Head Comparison

The table below covers the key clinical and practical differences for UAE residents choosing between these two drugs. WIN marks the stronger option per category; TIE marks categories where both drugs are equivalent.

Feature	Tirzepatide (Mounjaro / Zepbound)	Semaglutide (Ozempic / Wegovy)
Mechanism	Dual GLP-1 + GIP agonist WIN	Single GLP-1 agonist
Mean weight loss (head-to-head)	20.2% body weight WIN	13.7% body weight
Source trial	SURMOUNT-5, NEJM 2025	SURMOUNT-5, NEJM 2025
Max approved weight-loss dose	15mg once weekly	2.4mg once weekly (Wegovy)
Injection frequency	Once weekly TIE	Once weekly
GI side effects	Nausea, vomiting, diarrhea TIE	Nausea, vomiting, diarrhea
Injection site reactions	Slightly more frequent	Less common WIN
Blood sugar reduction (HbA1c)	Greater reduction WIN	Significant but smaller
Cardiovascular outcome data	SURPASS-CVOT ongoing; promising interim results	SELECT trial: 20% reduction in major CV events WIN
UAE (MOHAP) approval	Approved TIE	Approved
Estimated UAE monthly cost	2,900–4,299 AED (maintenance dose)	1,800–3,500 AED (Wegovy) WIN
Prescription required (UAE)	Yes TIE	Yes

Are the Side Effects of Tirzepatide Worse Than Ozempic?

Based on SURMOUNT-5 trial data, the side effect profiles are broadly comparable. Gastrointestinal effects — nausea, vomiting, constipation, and diarrhea — occurred at similar rates in both groups. Around 10–15% of participants discontinued each drug due to side effects, consistent with earlier individual trials (NEJM, 2025). For a detailed breakdown of what to expect week by week, see our tirzepatide side effects guide.

When side effects peak

Both drugs cause the most discomfort during the first four to six weeks of each dose escalation. Most people find nausea peaks around two weeks after a dose increase, then fades considerably. Starting at the lowest dose (2.5mg for tirzepatide, 0.25mg for semaglutide) and titrating slowly is standard practice. Smaller meals and avoiding high-fat foods during the first weeks helps a great deal.

The differences worth knowing

Tirzepatide users in SURMOUNT-5 reported slightly higher rates of injection-site reactions — mild redness and itching at the injection point. Semaglutide users reported marginally more nausea at doses that deliver equivalent weight-loss outcomes. Neither difference is dramatic. Pancreatitis is a rare but serious risk with both medications, and both carry a theoretical thyroid C-cell tumour risk based on rodent studies.

How Do the Costs Compare in the UAE?

Semaglutide has a modest price advantage in the UAE, though that gap is narrowing as tirzepatide availability improves. Wegovy (semaglutide 2.4mg) runs approximately 1,800–3,500 AED per month at Dubai clinics, while Mounjaro (tirzepatide) at the 10–15mg maintenance dose runs 2,900–4,299 AED per month (Dubai Health Authority, 2025). When you calculate cost-per-kilogram-lost using SURMOUNT-5 outcomes, tirzepatide's higher efficacy partially closes that price gap.

Insurance coverage in the UAE

Most UAE insurance plans don't cover GLP-1 medications for weight loss unless a type 2 diabetes diagnosis is documented. Ozempic has broader coverage because it has longer-established diabetes approval. Tirzepatide coverage is improving but remains inconsistent across insurers. Check your policy before committing to either drug — the out-of-pocket cost difference adds up significantly over a 72-week course.

These are long-term commitments

Most clinical trials ran for 72 weeks. Stopping either medication typically leads to significant weight regain. One study found patients regained around two-thirds of lost weight within a year of stopping semaglutide (The Lancet Diabetes and Endocrinology, 2022). Factor ongoing costs into your planning. These aren't short-term interventions.

Which Should You Choose as a UAE Expat?

For most patients whose primary goal is maximum weight loss and who have no major cardiovascular contraindications, the SURMOUNT-5 data points toward tirzepatide. It produced roughly 6 kg more weight lost over 72 weeks in a direct controlled comparison — that's not a marginal difference. Semaglutide, however, has the stronger cardiovascular outcome data: the SELECT trial showed a 20% reduction in major cardiovascular events in patients with obesity and established heart disease (NEJM, 2023). For sourcing options in Dubai, see our guide on how to buy tirzepatide in Dubai.

There's a practical factor that doesn't appear in any clinical trial: supply consistency in the UAE market. We've found that Ozempic (semaglutide) has experienced repeated pharmacy shortages in Dubai and Abu Dhabi over the past two years due to global demand spikes. Tirzepatide supply has been notably more stable in the UAE through 2025 and into 2026. If you've had a prescription interrupted by a stock-out, that experience is worth factoring into your choice.

When semaglutide still makes more sense

Semaglutide is the right choice if you've already responded well to it and don't want to change. It's also appropriate if your cardiologist specifically recommends it based on the SELECT cardiovascular data. And if budget is the real constraint, semaglutide's lower monthly cost makes a full sustained course more financially manageable. Don't let a trial headline override your individual clinical context.

What about switching from semaglutide to tirzepatide?

Switching is done in practice, but there's no universal consensus on bridging protocols. Most UAE endocrinologists restart from the 2.5mg tirzepatide starting dose and retitrate slowly — usually over 16–20 weeks to reach maintenance. Rushing the transition amplifies GI side effects. Always discuss timing with your doctor. The full titration schedule is in our tirzepatide dosage guide.

Frequently Asked Questions

The Bottom Line for UAE Expats

The science has caught up with the debate. Tirzepatide produces greater weight loss than semaglutide — confirmed now by a direct head-to-head trial, not extrapolated from separate studies. If you're starting GLP-1 therapy in Dubai and body weight reduction is your primary goal, the current evidence points toward tirzepatide as the stronger option in 2026.

That said, "better in a trial" doesn't always mean "better for you." Semaglutide has more mature cardiovascular safety data, broader insurance coverage in the UAE, and a modest cost advantage. Individual responses vary. Some people do exceptionally well on semaglutide and have no reason to switch. Others plateau and find tirzepatide delivers the outcome they needed.

Don't make this decision based on a comparison article alone. Both drugs require a prescription and medical supervision in the UAE. Find a Dubai-based endocrinologist or obesity medicine specialist, bring the SURMOUNT-5 data to your appointment, and agree on a protocol that fits your health profile and financial reality.